Get research updatesAttention-deficit/hyperactivity disorder (ADHD) involves persistent difficulties with attention, impulsivity or restlessness that can affect everyday life.
An Open-label, Single Ascending Dose, Pharmacokinetic and Tolerability Study of NFC-1 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including MaitlandResearchers studied SPN-810, tracking side effects to assess safety and tolerability in children with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including BradentonA Phase II, Randomized, Double-Blind, Multi-center, Placebo-controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockA Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention Deficit Hyperactivity Disorder (ADHD)
This study has finished and is no longer accepting participants.
Location not clearly listedResearchers compared SPD503 (Guanfacine hydrochloride) (2 mg), SPD503 (3 mg), SPD503 (4 mg) and placebo to find out how the approaches affected ADHD symptoms in children and adolescents with ADHD.
This study has finished and is no longer accepting participants.
Location not clearly listedThis study evaluated the safety and effectiveness of CTN SR for people with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including Newport BeachA Phase III, Multi-center, Open-label Study of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study has finished and is no longer accepting participants.
Location not clearly listedA Phase II, Open-Label Co-Administration Study of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study has finished and is no longer accepting participants.
Location not clearly listedA Phase III, Multi-center, 12-month, Open-label Safety Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).
This study has finished and is no longer accepting participants.
Location not clearly listedResearchers compared SPD503 (Guanfacine HCl) and placebo, tracking side effects to assess safety and tolerability in children and adolescents with ADHD.
This study has finished and is no longer accepting participants.
Location not clearly listed
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
This study has finished and is no longer accepting participants.
Multiple locations, including DothanAn Exploratory Study to Assess the Sustained Effects of Digital Therapy in Pediatric Subjects 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
This study has finished and is no longer accepting participants.
Multiple locations, including ScottsdaleWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.